% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Cicala:301317,
author = {C. M. Cicala and S. Bauer$^*$ and M. C. Heinrich and C.
Serrano},
title = {{G}astrointestinal {S}tromal {T}umor: {C}urrent
{A}pproaches and {F}uture {D}irections in the {T}reatment of
{A}dvanced {D}isease.},
journal = {Hematology, oncology clinics of North America},
volume = {39},
number = {4},
issn = {0889-8588},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-00989},
pages = {773-784},
year = {2025},
note = {Volume 39, Issue 4, August 2025, Pages 773-784},
abstract = {This review discusses the current and future landscape of
advanced gastrointestinal stromal tumor (GIST) treatment. It
covers the role of tyrosine kinase inhibitors (TKIs),
specifically imatinib, and further treatment options, such
as sunitinib, regorafenib, and ripretinib, as well as
avapritinib for platelet-derived growth factor receptor
alpha D842V mutations. In addition, this review emphasizes
individualized treatment strategies within multidisciplinary
expert teams, including surgery and other locoregional
therapies, together with the importance of mutation-guided
approaches, particularly for wild-type GISTs. Finally, it
explores the potential of next-generation KIT inhibitors,
combination therapies, and other investigational
approaches.},
subtyp = {Review Article},
keywords = {Gastrointestinal stromal tumor (GIST) (Other) / Imatinib
(Other) / KIT mutation (Other) / PDGFRA mutation (Other) /
Targeted therapy (Other) / Tyrosine-kinase inhibitors (TKIs)
(Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40368739},
doi = {10.1016/j.hoc.2025.04.006},
url = {https://inrepo02.dkfz.de/record/301317},
}